Liver injury in COVID-19: clinical features and treatment management

Dongdong Yu; Qingru Du; Shengguang Yan; Xu-Guang Guo; Yehao He; Guodong Zhu; Kewei Zhao; Shi Ouyang

doi:10.1186/s12985-021-01593-1

Liver injury in COVID-19: clinical features and treatment management

Virol J. 2021 Jun 9;18(1):121. doi: 10.1186/s12985-021-01593-1.

Authors

Dongdong Yu^#¹, Qingru Du^#^{2

3}, Shengguang Yan^#⁴, Xu-Guang Guo⁵, Yehao He⁶, Guodong Zhu^{7

8}, Kewei Zhao⁹, Shi Ouyang¹⁰

Affiliations

¹ Department of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.
² Department of Infection Disease, The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangzhou, 510150, China.
³ Department of Preventive Medicine, School of Public Health, Guangzhou Medical University, Guangzhou, 510150, China.
⁴ School of Public Health, North China University of Science and Technology, Tangshan, 063210, Hebei, China.
⁵ Department of Clinical Laboratory Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.
⁶ Department of Clinical Laboratory Medicine, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.
⁷ Departments of Geriatrics and Oncology, Guangzhou First People's Hospital, Guangzhou, 510180, China.
⁸ School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
⁹ The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510378, Guangdong, China.
¹⁰ Department of Infection Disease, The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangzhou, 510150, China. ouyangshi@gzhmu.edu.cn.

^# Contributed equally.

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread to many countries around the world. In addition to lung disease, severe cases also displayed varying degrees of liver injury. This article will describe the latest developments regarding coronavirus and the pathogenesis of liver injury, the prone population and clinical characteristics of these patients, as well as providing some suggestions for clinical treatment.

Keywords: COVID-19; Liver injury; SARS-CoV2.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antiviral Agents / adverse effects
Antiviral Agents / therapeutic use
COVID-19 / complications*
Chemical and Drug Induced Liver Injury / pathology
Female
Humans
Incidence
Liver Diseases / diagnosis
Liver Diseases / etiology*
Liver Diseases / therapy
Male
Medicine, Chinese Traditional / adverse effects
SARS-CoV-2*

Substances

Antiviral Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding